Bausch & Lomb opened higher at $21.36, compared with its previous close of $21.32. In the last trading session, the stock traded between $20.82 and $21.38. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Bausch & Lomb is now worth
$ 105.73
Giving a profit of
$ 5.73 (5.73%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-0.17 (-0.81%)
Day High
$21.38
Day Low
$20.82
Day Open
$21.36
Prev Close
$21.32
Volume
7,34,923
1W Return
2.59%
1M Return
31.61%
3M Return
25.39%
6M Return
31.92%
1Y Return
28.71%
Market Cap ($ Mn)
7,560
PE Ratio
-
PB Ratio
0.96
PEG Ratio
-
ROE
-5.47%
ROCE
0.77%
EPS (TTM)
$0.09
1 Week
2.59%
1 Month
31.61%
3 Months
25.39%
6 Months
31.92%
9 Months
24.17%
HC Wainwright downgrades Bausch & Lomb to Neutral, raises target to $22
HC Wainwright downgraded Bausch & Lomb from Buy to Neutral. Price target raised from $21 to $22 by analyst Yi Chen. RBC Capital recently raised target to $23 with Outperform rating. Divergent analyst views emerge on stock outlook.
10 days agoBausch & Lomb raises FY26 sales guidance to $5.450B-$5.550B
Bausch & Lomb raised FY2026 sales guidance to $5.450 billion-$5.550 billion. New guidance is above the prior range of $5.440 billion-$5.540 billion. Updated outlook remains below the analyst consensus estimate of $5.495 billion. Q3 adjusted EPS rose 88.89% YoY to $0.34, beating estimates by 61.9%.
15 days agoThird Point buys Bausch + Lomb shares ahead of interim CEO appointment
Third Point acquired ~85,000 shares worth $1.4 million in Q2. Thomas J. Appio appointed interim CEO effective Oct. 12. Full-year 2026 adjusted EBITDA guidance expected to increase. EPS estimated at 22 cents, up from 18 cents YoY. Stock trails peer group average return by 45.91 percentage points.
24 days agoBausch + Lomb shares fall 10% on unexpected CEO change
Bausch + Lomb shares fell nearly 10% after Thomas J. Appio was appointed interim CEO. Brent Saunders departed as CEO following mutual agreement with the board. Both companies plan to raise full-year 2026 adjusted EBITDA guidance. Preliminary third-quarter performance was strong, but specific forecasts remain undisclosed. Bausch Health shares dropped 2.15%, significantly less than the subsidiary's decline.
1mo agoBausch + Lomb says FDA supportive of oral dry AMD drug study design
FDA supports initial study design for BL1243 oral treatment. Clinical program initiation planned for 2027. Prior safety data exists from ~2,100 participants. Oral route offers non-invasive alternative to injections.
1mo agoBausch + Lomb sets Oct 28 for Q3FY26 earnings release
Bausch + Lomb Corporation will release Q3FY26 financial results on October 28, 2026. Conference call and webcast scheduled for 8:00 am ET on the same day. Materials available on the Investor Relations website prior to the call. Replay available until November 11, 2026.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Bausch & Lomb is now worth
$ 105.73
Giving a profit of
$ 5.73 (5.73%)
Note: Past profits do not guarantee future returns.
